Genterapi til sygdomme i centralnervesystemet

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Genterapi til sygdomme i centralnervesystemet. / Nissen, Kristoffer; Klem, Louise; Jeppesen, Rose; Axelsen, Tobias Melton; Christiansen, Søren Hofmann; Gøtzsche, Casper Rene; Pinborg, Lars; Jespersen, Bo; Klemp, Kristian; Woldbye, David.

In: Ugeskrift for Laeger, Vol. 182, No. 3, V09190535, 2020.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Nissen, K, Klem, L, Jeppesen, R, Axelsen, TM, Christiansen, SH, Gøtzsche, CR, Pinborg, L, Jespersen, B, Klemp, K & Woldbye, D 2020, 'Genterapi til sygdomme i centralnervesystemet', Ugeskrift for Laeger, vol. 182, no. 3, V09190535. <https://ugeskriftet.dk/files/scientific_article_files/2020-02/v09190535ny.pdf>

APA

Nissen, K., Klem, L., Jeppesen, R., Axelsen, T. M., Christiansen, S. H., Gøtzsche, C. R., Pinborg, L., Jespersen, B., Klemp, K., & Woldbye, D. (2020). Genterapi til sygdomme i centralnervesystemet. Ugeskrift for Laeger, 182(3), [V09190535]. https://ugeskriftet.dk/files/scientific_article_files/2020-02/v09190535ny.pdf

Vancouver

Nissen K, Klem L, Jeppesen R, Axelsen TM, Christiansen SH, Gøtzsche CR et al. Genterapi til sygdomme i centralnervesystemet. Ugeskrift for Laeger. 2020;182(3). V09190535.

Author

Nissen, Kristoffer ; Klem, Louise ; Jeppesen, Rose ; Axelsen, Tobias Melton ; Christiansen, Søren Hofmann ; Gøtzsche, Casper Rene ; Pinborg, Lars ; Jespersen, Bo ; Klemp, Kristian ; Woldbye, David. / Genterapi til sygdomme i centralnervesystemet. In: Ugeskrift for Laeger. 2020 ; Vol. 182, No. 3.

Bibtex

@article{db559d69dfd24726a19365564e9d8f37,
title = "Genterapi til sygdomme i centralnervesystemet",
abstract = "In recent years, gene therapy has resurged as a potential treatment for an increasing number of medical diseases including those affecting the central nervous system (CNS), which is discussed in this review. Clinical trials have revealed promising results particularly in gene therapy for Parkinson's disease with upregulation of dopamine synthesis or downregulation of huntingtin synthesis in Huntington's disease. Gene therapy for spinal motor atrophy has received FDA approval this year. The biggest success is seen in ophthalmology, where gene therapy has been FDA/EU-approved for retinitis pigmentosa, sparking further hope of use for other CNS diseases in a near future.",
author = "Kristoffer Nissen and Louise Klem and Rose Jeppesen and Axelsen, {Tobias Melton} and Christiansen, {S{\o}ren Hofmann} and G{\o}tzsche, {Casper Rene} and Lars Pinborg and Bo Jespersen and Kristian Klemp and David Woldbye",
year = "2020",
language = "Dansk",
volume = "182",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "3",

}

RIS

TY - JOUR

T1 - Genterapi til sygdomme i centralnervesystemet

AU - Nissen, Kristoffer

AU - Klem, Louise

AU - Jeppesen, Rose

AU - Axelsen, Tobias Melton

AU - Christiansen, Søren Hofmann

AU - Gøtzsche, Casper Rene

AU - Pinborg, Lars

AU - Jespersen, Bo

AU - Klemp, Kristian

AU - Woldbye, David

PY - 2020

Y1 - 2020

N2 - In recent years, gene therapy has resurged as a potential treatment for an increasing number of medical diseases including those affecting the central nervous system (CNS), which is discussed in this review. Clinical trials have revealed promising results particularly in gene therapy for Parkinson's disease with upregulation of dopamine synthesis or downregulation of huntingtin synthesis in Huntington's disease. Gene therapy for spinal motor atrophy has received FDA approval this year. The biggest success is seen in ophthalmology, where gene therapy has been FDA/EU-approved for retinitis pigmentosa, sparking further hope of use for other CNS diseases in a near future.

AB - In recent years, gene therapy has resurged as a potential treatment for an increasing number of medical diseases including those affecting the central nervous system (CNS), which is discussed in this review. Clinical trials have revealed promising results particularly in gene therapy for Parkinson's disease with upregulation of dopamine synthesis or downregulation of huntingtin synthesis in Huntington's disease. Gene therapy for spinal motor atrophy has received FDA approval this year. The biggest success is seen in ophthalmology, where gene therapy has been FDA/EU-approved for retinitis pigmentosa, sparking further hope of use for other CNS diseases in a near future.

M3 - Tidsskriftartikel

C2 - 32052730

VL - 182

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 3

M1 - V09190535

ER -

ID: 260117127